ProCE Banner Activity

Advancing Inflammatory Bowel Disease Management: Clinical Takeaways on Emerging Therapies for CD and UC

Clinical Thought

Learn how the treatment landscape for inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, continues to evolve as more biologics targeting specific pathways (eg, IL-23, JAK, TL1A) offer promise in patients’ ability to achieve clinical remission and mucosal healing.

Released: March 26, 2025

Expiration: March 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with the American Gastroenterological Association (AGA)

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Partners

AGA

ProCE Banner

Disclosure

Primary Author

Jordan E. Axelrad, MD, MPH, FACG: consultant/advisor/speaker: AbbVie, Abviax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, Vedanta; researcher: BioFire Diagnostics, Genentech, Janssen.